香港股市 已收市

ACADIA Pharmaceuticals Inc. (ACAD)

NasdaqGS - NasdaqGS 即時價格。貨幣為 USD。
加入追蹤清單
18.26+0.06 (+0.33%)
市場開市。 截至 01:07PM EDT。
全螢幕
交易股價資料並非來自所有市場
前收市價18.20
開市18.20
買盤18.24 x 100
賣出價18.31 x 100
今日波幅18.05 - 18.42
52 週波幅17.56 - 33.99
成交量375,912
平均成交量1,870,432
市值3.009B
Beta 值 (5 年,每月)0.40
市盈率 (最近 12 個月)
每股盈利 (最近 12 個月)-0.37
業績公佈日2024年5月06日 - 2024年5月10日
遠期股息及收益率無 (無)
除息日
1 年預測目標價29.54
  • InvestorPlace

    3 Pharma Stocks to Sell in March Before They Crash & Burn

    Recent trends in the stock market have seen a shift in investor interest from tech giants, known as the Magnificent 7, towards pharmaceutical companies, particularly those involved in weight-loss drugs. But, it’s important to identify which pharma stocks to sell before they plummet, as not all will benefit equally from the hype. As a result, pharmaceutical companies like Eli Lilly (NYSE:LLY), Pfizer (NYSE:PFE) and Novo Nordisk (NYSE:NVO) are attracting retail investors’ attention given their por

  • Investor's Business Daily

    Acadia Hits 11-Month Low After Outsized Placebo Effect Torpedoes Schizophrenia Study

    Acadia stock crashed Tuesday after an outsized placebo effect torpedoed the company's efforts to expand Nuplazid to schizophrenia patients.

  • Reuters

    UPDATE 2-Acadia to stop trials of antipsychotic drug after it fails schizophrenia study

    Acadia Pharmaceuticals said on Monday it does not plan to conduct further clinical trials of its antipsychotic drug, pimavanserin, after it failed to improve negative symptoms of schizophrenia in a late-stage study. The decision comes after two failed attempts to secure regulatory approval for the expanded use of pimavanserin in the treatment of psychosis related to dementia and Alzheimer's disease in 2021 and 2022, respectively. In the current study that involved 454 adult patients, pimavanserin did not outperform a placebo in reducing negative symptoms of schizophrenia, including poor socialization and lack of motivation, Acadia said.